Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma.

J Dermatol · 2025 · PMC12231920 · PMID 40366077

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients with more advanced (IIIC–D) disease showed a potential trend toward poorer recurrence‐free survival (HR, 1.42; 95% CI, 0.84–2.39; p = 0.188), although this difference did not reach statistical significance (Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.